Literature DB >> 12969137

Early aldosterone up-regulated genes: new pathways for renal disease?

Markus Kellner1, Angela Peiter, Mathias Hafner, Martin Feuring, Michael Christ, Martin Wehling, Elisabeth Falkenstein, Ralf Lösel.   

Abstract

BACKGROUND: The use of aldosterone antagonists has important beneficial effects on the progression of renal and cardiac disease reflected in a decrease of cardiovascular mortality and renal failure. Nevertheless, the incidence of heart and end-stage renal failure continues to increase. This leads to the conclusion that mechanisms independent of the classical aldosterone/mineralocorticoid receptor system may contribute to the pathogenesis of cardiac and renal disease.
METHODS: The mRNA expression profile of human renal epithelial cells in response to aldosterone was characterized using cDNA arrays covering approximately 1430 genes. Differentially expressed genes were further evaluated by quantitative reverse transcription-polymerase chain reaction (RT-PCR), Northern blotting, and estimating the gene products by Western blotting.
RESULTS: Aldosterone treatment of cells resulted in significant up-regulation of several genes within 1 hour, with sgk, p21/waf1, gadd45, and gadd153 being the most significant ones. Long-term treatment (>4 hours) with aldosterone induced the mRNA expression of pparalpha and puralpha. The mineralocorticoid receptor inhibitor spironolactone decreased the mRNA levels of sgk, p21/waf1, and gadd45, whereas the glucocorticoid receptor inhibitor RU 486 reduced the mRNA level of sgk and p21/waf1. Gadd153 was not affected by any of the inhibitors, probably indicating regulation by nonclassic mechanisms.
CONCLUSION: Among the early genes investigated in this study, one transcript has been identified that is not suppressed by antagonists of either glucocorticoid or mineralocorticoid receptor. Further studies should be able to identify other genes regulated in a similar manner that could explain the inefficacy of spironolactone in some cases of aldosterone-mediated kidney disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969137     DOI: 10.1046/j.1523-1755.2003.00216.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Mineralocorticoid receptor antagonizes Dot1a-Af9 complex to increase αENaC transcription.

Authors:  Xi Zhang; Qiaoling Zhou; Lihe Chen; Stefan Berger; Hongyu Wu; Zhou Xiao; David Pearce; Xiaodong Zhou; Wenzheng Zhang
Journal:  Am J Physiol Renal Physiol       Date:  2013-09-11

Review 2.  Regulation of αENaC transcription.

Authors:  Lihe Chen; Xi Zhang; Wenzheng Zhang
Journal:  Vitam Horm       Date:  2015-02-14       Impact factor: 3.421

Review 3.  Aldosterone-induced fibrosis in the kidney: questions and controversies.

Authors:  Andrew S Brem; David J Morris; Rujun Gong
Journal:  Am J Kidney Dis       Date:  2011-06-25       Impact factor: 8.860

4.  Dot1a contains three nuclear localization signals and regulates the epithelial Na+ channel (ENaC) at multiple levels.

Authors:  Mary Rose Reisenauer; Steven W Wang; Yang Xia; Wenzheng Zhang
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-28

5.  Aldosterone-sensitive repression of ENaCalpha transcription by a histone H3 lysine-79 methyltransferase.

Authors:  Wenzheng Zhang; Xuefeng Xia; Diana I Jalal; Teresa Kuncewicz; William Xu; Gene D Lesage; Bruce C Kone
Journal:  Am J Physiol Cell Physiol       Date:  2005-10-19       Impact factor: 4.249

6.  SGK1-sensitive renal tubular glucose reabsorption in diabetes.

Authors:  Teresa F Ackermann; Krishna M Boini; Harald Völkl; Madhuri Bhandaru; Petra M Bareiss; Lothar Just; Volker Vallon; Kerstin Amann; Dietmar Kuhl; Yuxi Feng; Hans-Peter Hammes; Florian Lang
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-21

7.  Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome.

Authors:  P Stiefel; A J Vallejo-Vaz; S García Morillo; J Villar
Journal:  Int J Hypertens       Date:  2011-06-23       Impact factor: 2.420

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.